Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EBITDA (2022 - 2025)

Historic EBITDA for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to -$51.1 million.

  • ARS Pharmaceuticals' EBITDA fell 17414.72% to -$51.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$80.4 million, marking a year-over-year decrease of 6538.97%. This contributed to the annual value of $8.2 million for FY2024, which is 11492.79% up from last year.
  • ARS Pharmaceuticals' EBITDA amounted to -$51.1 million in Q3 2025, which was down 17414.72% from -$45.0 million recorded in Q2 2025.
  • ARS Pharmaceuticals' EBITDA's 5-year high stood at $49.8 million during Q4 2024, with a 5-year trough of -$51.1 million in Q3 2025.
  • Its 4-year average for EBITDA is -$14.1 million, with a median of -$14.0 million in 2022.
  • As far as peak fluctuations go, ARS Pharmaceuticals' EBITDA soared by 81593.85% in 2024, and later tumbled by 25894.55% in 2025.
  • Quarter analysis of 4 years shows ARS Pharmaceuticals' EBITDA stood at -$14.0 million in 2022, then surged by 50.38% to -$7.0 million in 2023, then skyrocketed by 815.94% to $49.8 million in 2024, then plummeted by 202.6% to -$51.1 million in 2025.
  • Its EBITDA stands at -$51.1 million for Q3 2025, versus -$45.0 million for Q2 2025 and -$34.1 million for Q1 2025.